Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC4116136: UMEC added to fluticasone propionate/salmeterol in COPD
2012-001871-35Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Trough FEV1 on treatment day 85. Started Dec 2012; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-001871-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001871-35.